Our lab focuses on novel gene editing techniques like CRISPR/Cas9 to understand the pathobiology of hematological diseases. Therefore, our lab developed robust and faithful human BCR/ABL and MLL rearranged models based on patient-specific translocations induced in hematopoietic stem and progenitor cells (HSPCs) derived from both cord blood and bone marrow. By using different microenvironments, we promote lymphatic and myeloid differentiation independently of the origin of the cell. These genome-edited cells authentically mimic adult and childhood patient disease and demonstrate unlimited in vitro growth potential. By using genetic analyses, we gain valuable knowledge about disease mechanisms uncovering novel therapeutic targets. Candidate compounds can be easily tested with our platforms allowing us to understand their mode of action with high translational character.
Another interest of our lab is the optimization of cellular therapies using innovative chimeric antigen receptor technologies targeting novel antigens for the treatment of acute leukemia. Hereby, we also focus on particular effector cell populations such as invariant natural killer T (iNKT) cells. iNKT cells are potent regulators of immune responses with strong cytotoxic properties that can be further increased by introducing chimeric antigen receptors. iNKT cells also prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation (HCT). We develop novel cytotherapeutic approaches to improve outcomes after allogeneic HCT by reducing relapse rates and non-relapse mortality.Publications
Are you interested in our research topics? Can you imagine becoming part of the Schneidawind laboratory as a master’s student, PhD student or postdoc?
Please contact us directly for further information or send your application to Corina Schneidawind.